title: PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
abstract: Blocking PcrV, an essential component of the Type III secretion system (TTSS), has demonstrated efficacy against Pseudomonas aeruginosa infections. However, most of the results came from laboratory strains. Whether it is applicable to clinically isolated multi-drug resistant (MDR) strains is unknown. In this study we investigated the expression level of TTSS in clinically isolated MDR P. aeruginosa strains and the effects of anti-PcrV antibody on MDR isolate induced acute lung injury (ALI). The expression level of TTSS was quantified in 53 isolates including 25 MDR strains and 28 susceptible strains. We investigated the effect of anti-PcrV antibody through a murine model induced by instillation of a MDR strain into the left lung through trachea. Our results showed that the expression level of TTSS in MDR strains is comparable to susceptible strains. Anti-PcrV ensured the survival of challenged mice, reduced the bacteria numbers and attenuated lung inflammation and injury. This study proved that anti-PcrV may be a potentially effective strategy against MDR P. aeruginosa induced ALI.
authors.affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Huayin
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Department of Surgical Intensive Care Unit, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Zhong
authors.affiliation: Department of Surgical Intensive Care Unit, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Duming
authors.initials: D
authors.lastname: Zhu
authors.affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Nana
authors.initials: N
authors.lastname: Feng
authors.affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Fanglei
authors.initials: F
authors.lastname: Liu
authors.affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: bai.chunxue@zs-hospital.sh.cn.
authors.forename: Chunxue
authors.initials: C
authors.lastname: Bai
authors.affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Pulmonary Medicine, Zhongshan Hospital, Qingpu Branch, Shanghai, China; Shanghai Public Health Clinical Center, Shanghai, China. Electronic address: song.yuanlin@zs-hospital.sh.cn.
authors.forename: Yuanlin
authors.initials: Y
authors.lastname: Song
mesh_terms: D036002:ADP Ribose Transferases / Q000378:metabolism; D055371:Acute Lung Injury / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000378:metabolism; D058947:Bacterial Secretion Systems / Q000502:physiology*; D001427:Bacterial Toxins / Q000276:immunology* / Q000378:metabolism; D002442:Ceftazidime / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood; D024901:Drug Resistance, Multiple, Bacterial; D015870:Gene Expression; D007116:Immunization, Passive; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000276:immunology; D052899:Pore Forming Cytotoxic Proteins / Q000276:immunology*; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000472:pathogenicity*; D013045:Species Specificity; D016019:Survival Analysis
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D058947:Bacterial Secretion Systems; D001427:Bacterial Toxins; D016207:Cytokines; D052899:Pore Forming Cytotoxic Proteins; C118546:antigen V, Pseudomonas; C111749:pseudomonas exoprotein A protein, Pseudomonas aeruginosa; D002442:Ceftazidime; D036002:ADP Ribose Transferases; C444820:exoenzyme S
keywords: Mab166; Multi-drug resistance; PcrV; Pseudomonas aeruginosa; Type III secretion system